Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
2024年ERS大会上，再生元公司重点展示呼吸道疾病管理方面的科学创新和领导力，展示杜璞生和伊替佩奥单抗。
- 20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
- Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups
- Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupixent on clinical remission, airway remodeling and mucus plugging starting at 4 weeks, as well as data from investigational therapy itepekimab in former smokers with COPD
- 提供20份摘要，包括4个口头报告，为慢性阻塞性肺疾病（COPD），哮喘和慢性鼻窦炎合并鼻息肉（CRSwNP）的治疗提供新的见解。
- 从Dupixent在COPD的重要第3期试验数据强化了减少恶化和改善肺功能的效果，并为患者亚组的健康相关生活质量提供了新的评估。
- 其他报告重点介绍了一项新颖的哮喘成像研究，显示Dupixent对临床缓解，气道重塑和黏液堵塞的早期影响从4周开始，以及来自治疗候选药itepekimab在老烟民患者中的COPD数据。
资讯热榜
更新时间